Zalmoxis

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
05-09-2016
Tabia za bidhaa Tabia za bidhaa (SPC)
05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma (PAR)
05-09-2016

Viambatanisho vya kazi:

Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)

Inapatikana kutoka:

MolMed SpA

ATC kanuni:

L01

INN (Jina la Kimataifa):

allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)

Kundi la matibabu:

Antineoplastic agents

Eneo la matibabu:

Hematopoietic Stem Cell Transplantation; Graft vs Host Disease

Matibabu dalili:

Zalmoxis is indicated as adjunctive treatment in haploidentical haematopoietic stem cell transplantation (HSCT) of adult patients with high-risk haematological malignancies.

Bidhaa muhtasari:

Revision: 1

Idhini hali ya:

Withdrawn

Idhini ya tarehe:

2016-08-18

Taarifa za kipeperushi

                                B. PACKAGE LEAFLET
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
ZALMOXIS
5-20 X 10
6 CELLS/ML DISPERSION FOR INFUSION
Allogeneic T cells genetically modified with a retroviral vector
encoding for a truncated form of the
human low affinity nerve growth factor receptor (ΔLNGFR) and the
herpes simplex I virus thymidine
kinase (HSV-TK Mut2)
This medicine is subject to additional monitoring. This will allow
quick identification of new
safety information. You can help by reporting any side effects you may
get. See the end of section 4
for how to report side effects.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, or a physician
experienced in the medical
treatment of blood cancer.
-
If you get any side effects, talk to your doctor, or a physician
experienced in the medical
treatment of blood cancer. This includes any possible side effects not
listed in this leaflet. See
section 4.
WHAT IS IN THIS LEAFLET
1.
What Zalmoxis is and what it is used for
2.
What you need to know before you are given Zalmoxis
3.
How Zalmoxis is given to you
4.
Possible side effects
5.
How to store Zalmoxis
6.
Contents of the pack and other information
1.
WHAT ZALMOXIS
IS AND WHAT IT IS USED FOR
Zalmoxis consists of white blood cells called T cells that are
obtained from the donor. These cells will
be genetically modified by introducing a “suicide” gene (HSV-TK
Mut2) in their genetic code which
can be activated later on in case of graft-versus-host disease. This
will ensure that the cells can be
eliminated before they can cause damage to the patient’s cells.
Zalmoxis is intended for use in adults with certain tumours of the
blood known as high-risk
haemotological malignancies. It is given after haploidentical bone
marrow transplantation
(haematopoietic cell transplantation). Haploidentical means that the
cells have been obtained from a
donor whose tissues part
                                
                                Soma hati kamili

Tabia za bidhaa

                                ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will
allow quick identification of
new safety information. Healthcare professionals are asked to report
any suspected adverse reactions.
See section 4.8 for how to report adverse reactions.
1.
NAME OF THE MEDICINAL PRODUCT
Zalmoxis 5-20 x 10
6
cells/mL dispersion for infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
2.1
GENERAL DESCRIPTION
Allogeneic T cells genetically modified with a retroviral vector
encoding for a truncated form of the
human low affinity nerve growth factor receptor (ΔLNGFR) and the
herpes simplex I virus thymidine
kinase (HSV-TK Mut2).
2.2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each bag of Zalmoxis contains a volume of 10-100 mL of frozen
dispersion at the concentration of
5-20 x 10
6
cells/mL. The cells are of human origin and genetically modified with
a replication-
defective γ-retroviral vector coding for the HSV-TK and ΔLNGFR genes
so that these sequences are
integrated in the genome of the host cells.
The cellular composition and the final cell number will vary according
to the weight of the patient. In
addition to T cells, NK cells and residual levels of monocytes and of
B cells may be present.
Excipient with known effect
_ _
Each bag contains approximately 13.3 mmol (305.63 mg) of sodium per
dose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Dispersion for infusion.
Opaque, off-white frozen dispersion.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Zalmoxis is indicated as adjunctive treatment in haploidentical
haematopoietic stem cell
transplantation (HSCT) of adult patients with high-risk haematological
malignancies (see section 5.1).
_ _
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Zalmoxis must be administered under the supervision of a physician
experienced in HSCT for
haematological malignancies.
Posology
The recommended dose and schedule is 1 ± 0.2 x 10
7
cells/kg given as an intravenous infusion at a
time interval of 21-49 days from
                                
                                Soma hati kamili

Bidhaa zinazofanana

Viambatanisho vya kazi Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)

Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)

ATC kanuni L01

L01

Mzalishaji au wazalishaji wadogowadogo MolMed SpA

MolMed SpA

INN (Jina la Kimataifa) allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)

allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kibulgaria 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kihispania 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kicheki 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kidenmaki 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kijerumani 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kiestonia 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kigiriki 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kifaransa 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kiitaliano 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kilatvia 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kilithuania 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kihungari 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kimalta 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kiholanzi 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kipolandi 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kireno 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kiromania 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kislovakia 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kislovenia 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kifinlandi 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kiswidi 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kinorwe 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 05-09-2016
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 05-09-2016
Tabia za bidhaa Tabia za bidhaa Kroeshia 05-09-2016
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 05-09-2016

Tafuta arifu zinazohusiana na bidhaa hii

Taadhari Zalmoxis Allogeneic cells genetically modified with retroviral vector encoding

Zalmoxis Allogeneic cells genetically modified with retroviral vector encoding

Tazama historia ya hati

Historia ya nyaraka Historia ya nyaraka

Zalmoxis